BlueRock Therapeutics

Vision

BlueRock is passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with few treatment options.

Approach

BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. The company’s cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome editing. This enables an approach where, in theory, any cell in the body can be manufactured and any gene in the genome can be engineered for therapeutic purposes. The platform is broadly applicable, but the company is focused today in neurology, cardiology, and immunology. In August 2019, the company was acquired by Bayer AG, for an enterprise value of $1B in upfront and milestone payments. For BlueRock this marks the next step in the journey to prove degenerative disease is reversible, and to bring revolutionary new medicines to the patients who desperately need them.

Since August 2019, BlueRock is a wholly-owned, independently operated subsidiary of Bayer as a cornerstone of its Cell & Gene Therapy Platform.

BlueRock Therapeutics is addressing

• Leap 02 / Provide sustainable organ and tissue replacement
• Leap 05 / Protect brain and mind